Communiqués GSK plc

Actions

GSK

GB00BN7SWP63

Produits pharmaceutiques

Marché Fermé - London S.E. Autres places de cotation 17:35:11 08/07/2026			Varia. 5j.	Varia. 1 janv.
1 979,50 ^GBX	-1,17%		-0,08%	+8,50%

08/07	Fin du partenariat entre Alector et GSK après l'échec de traitements contre la démence et Alzheimer	RE
08/07	Les bourses européennes clôturent en forte baisse mercredi ; les prix du pétrole s'envolent avec la reprise du conflit entre les États-Unis et l'Iran	MT

Communiqués

24/06	GSK : announces commencement of tender offer to acquire Nuvalent, Inc.	PU
17/06	Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)	BU
17/06	GSK : Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)	PU
01/06	PrEP Wisdom: ViiV Healthcare Launches New Campaign to Support Informed HIV Prevention Choices	BU
28/05	GSK : Bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B	PU
26/05	GSK : to showcase long-term outcomes and pipeline expansion with latest oncology research at ASCO and EHA	PU
18/05	GSK : RSV vaccine, Arexvy, receives expanded approval in Japan for adults aged 18–59 at increased risk	PU
11/05	GSK : enters exclusive collaboration with SBP Group, a market leader in hepatology in China, to accelerate bepirovirsen at launch	PU
07/05	Julie Bowen and Ty Burrell team up with GSK to raise awareness about meningitis risks for teens and young adults	BU
06/05	GSK : 2026 Remuneration Policy	PU
06/05	GSK : presents latest respiratory research to advance patient care at ATS 2026	PU
30/04	GSK : Q1 2026 results transcript	PU
29/04	The Fifth International Healthcare Week set for next month	AQ
29/04	Glaxo: Q1 Earnings Snapshot	AQ
29/04	GSK : Q1 2026 results slides	PU
29/04	GSK : Q1 2026 pipeline assets and clinical trials report	PU
29/04	GSK : Q1 2026 results infographic	PU
29/04	GSK : Q1 2026 US dollar translation	PU
29/04	GSK : delivers strong Q1 performance and start to 2026	PU
28/04	GSK : Bepirovirsen accepted for priority review and granted Breakthrough Therapy Designation by the US FDA	PU
27/04	GSK : investigational liver therapy, efimosfermin, receives US FDA Breakthrough Therapy and EMA Priority Medicines (PRIME) designations for MASH	PU
12/04	GSK : presents positive data for B7-H4-targeted ADC in gynaecological cancers	PU
10/04	The Time to Talk about HIV is Now: ViiV Healthcare Launches "Still Here" PSA to Ignite Action Around HIV on National Youth HIV/AIDS Awareness Day	BU
09/04	GSK : Q1 2026 pre announcement aide memoire	PU
30/03	GSK plc - Bepirovirsen accepted for review by the European Medicines Agency as a potential first-in-class treatment for chronic hepatitis B	AQ